Last updated: May 29, 2026

Application No. 18/312,305

COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS

Final Rejection

Filed

May 04, 2023

Priority

Mar 22, 2021 — provisional 63/164,523 +4 more

Examiner

SHIN, DANA H

Art Unit

1635

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Recode Therapeutics Inc.

OA Round

5 (Final)

Interview Optional

— +27.6% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 27% grant rate with +27.6% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.

Based on 1155 resolved cases, 2023–2026

Examiner Intelligence

SHIN, DANA H View full profile →

Grants only 27% of cases

Career Allowance Rate

314 granted / 1155 resolved

-32.8% vs TC avg

Strong +28% interview lift

Without

With

+27.6%

Interview Lift

resolved cases with interview

Typical timeline

3y 3m

Avg Prosecution

72 currently pending

Career history

1239

Total Applications

across all art units

Statute-Specific Performance

§101

6.0%

-34.0% vs TC avg

§103

37.6%

-2.4% vs TC avg

§102

5.6%

-34.4% vs TC avg

§112

18.8%

-21.2% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1155 resolved cases

Prosecution Timeline

Show 5 earlier events

Feb 12, 2024

Non-Final Rejection mailed

May 10, 2024

Response Filed

Jun 05, 2024

Final Rejection mailed

Oct 21, 2024

Request for Continued Examination

Oct 22, 2024

Response after Non-Final Action

Mar 14, 2025

Non-Final Rejection mailed

Aug 04, 2025

Response Filed

Sep 08, 2025

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

16/474,686

Patent 12624068

EXON SKIPPING BY PEPTIDE NUCLEIC ACID DERIVATIVES

6y 10m to grant Granted May 12, 2026

16/966,506

Patent 12617841

NUCLEIC ACID ANTIBODY CONSTRUCTS FOR USE AGAINST RESPIRATORY SYNCYTIAL VIRUS

5y 9m to grant Granted May 05, 2026

18/058,000

Patent 12612656

PARTICLE-BASED ISOLATION OF PROTEINS AND OTHER ANALYTES

3y 5m to grant Granted Apr 28, 2026

18/177,446

Patent 12582723

NOVEL POLYNUCLEOTIDES ENCODING A HUMAN FKRP PROTEIN

3y 0m to grant Granted Mar 24, 2026

15/764,429

Patent 12527834

POLYAMINATED POLYGLUTAMIC ACID-CONTAINING COMPOUNDS AND USES THEREOF FOR DELIVERING OLIGONUCLEOTIDES

7y 9m to grant Granted Jan 20, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

6-7

Expected OA Rounds

27%

Grant Probability

55%

With Interview (+27.6%)

3y 3m (~2m remaining)

Median Time to Grant

High

PTA Risk

Based on 1155 resolved cases by this examiner. Grant probability derived from career allowance rate.